ALXO · NASDAQ
ALX Oncology Holdings (ALXO) Stock Price & Fundamentals
ALX Oncology Holdings (ALXO) closed at $489.57 on Oct 9, 2026, down 1.33% from the previous close of $496.15.
Share price, past year
1Y −13.63%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $489.57 |
| Sep 30, 2026 | $486.74 |
| Aug 31, 2026 | $498.41 |
| Jul 31, 2026 | $494.14 |
| Jun 30, 2026 | $513.22 |
| May 29, 2026 | $556.83 |
| Apr 30, 2026 | $576.58 |
| Mar 31, 2026 | $597.02 |
| Feb 27, 2026 | $589.75 |
| Jan 30, 2026 | $603.04 |
| Dec 31, 2025 | $611.84 |
| Nov 28, 2025 | $554.95 |
| Oct 31, 2025 | $571.94 |
Key statistics
- Market cap
- $67.67B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.13
- Revenue (TTM)
- —
- Net income (TTM)
- −$80.89M
- Shares outstanding
- 138.2M
- Dividend yield
- —
- 52-week range
- $483.30 – $629.95
ALX Oncology Holdings's market cap is $67.67B, based on a share price of $489.57 and 138.2M shares outstanding as of Jun 30, 2026.
Financials
ALX Oncology Holdings reported revenue of $0.00 for fiscal 2022.
ALX Oncology Holdings reported a net loss of $101.70M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2022ended Dec 31, 2022 | $0.00 | — | −$123.48M | — | −$3.03 | −$90.65M |
| FY2021ended Dec 31, 2021 | $0.00 | −100.0% | −$83.46M | — | −$2.07 | −$68.77M |
| FY2020ended Dec 31, 2020 | $1.18M | −75.4% | −$45.74M | −3,869.7% | −$2.76 | −$38.32M |
| FY2019ended Dec 31, 2019 | $4.80M | +132.0% | −$19.24M | −401.2% | −$7.56 | −$14.60M |
| FY2018ended Dec 31, 2018 | $2.07M | — | −$13.73M | −664.3% | −$6.33 | −$13.84M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2020ended Jun 30, 2020 | $527.00K | — | — |
| Q1 FY2020ended Mar 31, 2020 | $655.00K | — | — |
| Q3 FY2019ended Sep 30, 2019 | $1.26M | — | — |
| Q2 FY2019ended Jun 30, 2019 | $1.30M | — | — |
Company profile
- Name
- ALX Oncology Holdings Inc.
- Ticker
- ALXO
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 323 Allerton Avenue, South San Francisco, CA 94080
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001810182
Recent SEC filings
- Aug 6, 2026
- Aug 6, 2026
- Jun 30, 2026
- Jun 26, 2026
- Jun 11, 2026
- May 8, 2026
- May 8, 2026
- Apr 13, 2026
Frequently asked questions
What is ALX Oncology Holdings's stock price?
ALX Oncology Holdings (ALXO) closed at $489.57 on Oct 9, 2026, down 1.33% from the previous close of $496.15.
What is ALX Oncology Holdings's market cap?
ALX Oncology Holdings's market cap is $67.67B, based on a share price of $489.57 and 138.2M shares outstanding as of Jun 30, 2026.
How much revenue does ALX Oncology Holdings make?
ALX Oncology Holdings reported revenue of $0.00 for fiscal 2022.
Does ALX Oncology Holdings pay a dividend?
ALX Oncology Holdings's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from ALX Oncology Holdings Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures